Developer docs
API playgroundTry for free, no card

Search company profiles

Quorum Innovations

Full company profile

uuid000bd46

Namestring
Quorum Innovations
Legal namestring
Quorum Innovations
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Quorum Innovations is a privately held microbiome biotherapeutics company headquartered in Sarasota, Florida, founded in 2011 by physician-scientists Dr. Nicholas Monsul and Dr. Eva Berkes. The company develops barrier-based microbiome technologies originating from two DARPA-funded research programs on protective biotherapeutics for military warfighters. Its flagship technology, the Biofilm Shield™, is a non-living, biofilm-derived postbiotic aggregate produced from heat-inactivated Lactobacillus fermentum (Qi6 strain), which has received FDA Generally Recognized as Safe designation under GRN 000988. The aggregate forms self-organizing macrostructures approximately 200 micrometers in diameter with a cobblestone-like surface topology that selectively binds micro- and nanoplastics in the gastrointestinal tract, reducing microplastic adherence to human intestinal epithelial cells by up to 83% in laboratory studies.

The company's commercial product, Qi601™, launched in 2025 and is sold directly to consumers as a once-daily oral postbiotic supplement via the proprietary e-commerce storefront qi601.com. Supporting technology platforms include the MiNE™ (Microbiome isolates and Novel Extracts) discovery engine and the Probiomic® biotherapeutic framework, both of which underpin the current product and a potential pipeline of additional barrier-defense candidates. The company holds over 55 issued patents across more than 50 countries and has active research collaborations with Bayer Pharmaceuticals in women's health, as well as participation in the HHS STOMP federal initiative on microplastics.

Quorum operates with 1–10 employees, sells only in the United States through direct-to-consumer channels, and generates revenue from one-time purchases and subscription orders of Qi601 capsules. Its business model is product-led and science-marketing-driven, emphasizing peer-reviewed clinical evidence, FDA GRAS status, and a patented mechanism of action rather than traditional retail distribution or institutional sales.

Short descriptiontext

Quorum Innovations is a Sarasota-based microbiome biotherapeutics company that sells Qi601™, an FDA GRAS-designated postbiotic supplement that binds microplastics in the gut, directly to health-conscious consumers via its qi601.com e-commerce storefront.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSarasota, United States
HQ citystring
Sarasota
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome biotherapeutics, postbiotic supplements, microplastic detox, biofilm shield technology, human microbiome research
Industry1 code
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Microbiome Therapeutics / Dietary Supplements
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Direct-to-Consumer Supplement Sales
TypeSubscription Recurring
Description

Quorum generates revenue through direct sales of Qi601 capsules to consumers via its e-commerce platform at qi601.com. The product is sold as a daily oral supplement with pricing for individual bottles and potentially subscription options for recurring purchases.

quoruminnovations.com
2Consumer Direct Sales
TypeOne Time License
Description

One-time purchase of Qi601 supplement bottles through the company's e-commerce storefront, targeting health-conscious individual consumers concerned about microplastic exposure.

quoruminnovations.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Qi601
Description

The world's first microplastic detox product - a patented, orally administered postbiotic derived from Lactobacillus fermentum that forms a biofilm shield to bind micro- and nanoplastics in the gut.

quoruminnovations.com
+3 more records
Core offering1 text field

Quorum Innovations develops and sells Qi601™, the world's first microplastic detox supplement. Qi601 is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum that forms a biofilm-like matrix in the gastrointestinal tract to bind and sequester micro- and nanoplastics, preventing their absorption into the body. The product is sold direct-to-consumer through the company's own e-commerce platform at qi601.com, supported by the proprietary MiNE™ discovery platform and Probiomic® biotherapeutic technology framework with 55+ issued patents worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 98% capture of nanoplastics in laboratory tests simulating digestive conditions
+3 more records
Product overview1 text field

Quorum Innovations develops microbiome biotherapeutics centered on its flagship product Qi601™ Biofilm Shield™ — a patented, orally administered postbiotic supplement that forms a non-systemic gut biofilm matrix to bind and sequester micro- and nanoplastics. The technology portfolio includes the MiNE™ (Microbiome isolates and Novel Extracts) discovery platform and the Probiomic® technology framework. Qi601™ represents the first commercial application, with the platform technologies supporting its development and enabling future biotherapeutic pipeline candidates for barrier defense applications.

Product and service1 record
1Qi601™
CategoryMicrobiome dietary supplement (microplastic detox product)
Description

Qi601™ is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum (GRN 000988) that forms self-aggregating biofilm macrostructures (~200 µm) in the gastrointestinal tract to physically bind and sequester micro- and nanoplastics, helping prevent their absorption into the human body. Sold direct-to-consumer through qi601.com as a once-daily capsule supplement.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1HHS STOMP Initiative
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Quorum Innovations was invited to participate in the HHS STOMP (Strategic Training for Opioid Microplastics) initiative in Washington D.C., recognizing the company as a subject matter expert on microplastics and human health. The company joins federal leadership and key stakeholders working to address microplastic exposure impacts, positioning Quorum at the forefront of national public health efforts.

quoruminnovations.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bayer Pharmaceuticals partnered with Quorum in a joint development program exploring biofilm barrier protection technologies for women's health applications in intimate care products. This collaboration validated the translational potential of Quorum's barrier defense platform beyond military applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Seed is a science-led DTC microbiome company selling probiotic and synbiotic supplements with subscription e-commerce. Like Quorum, it markets clinically validated microbiome products directly to health-conscious consumers and emphasizes peer-reviewed research in its positioning.

TypeBroad incumbent
Description

Finch develops microbiome-based therapeutics with a focus on consortia-based drug products. It shares Quorum's microbiome therapeutics DNA but operates at a larger scale with a broader R&D pipeline and more established pharma partnerships.

3Align (Procter & Gamble)
TypeBroad incumbent
Description

Align is a leading digestive health probiotic brand owned by Procter & Gamble. It targets the same health-conscious consumer seeking gut health benefits but at mass-market scale across food, drug, and mass retail channels.

4Culturelle (i-Health / Chr. Hansen)
TypeBroad incumbent
Description

Culturelle is one of the largest clinically-backed probiotic supplement brands, owned by i-Health and now part of Chr. Hansen. It competes in the same digestive health probiotic category but with vastly broader retail distribution and brand recognition.

TypeEmerging player
Description

Symbiome is a microbiome-focused consumer brand founded by Larry Weiss, who serves as a Scientific Advisor to Quorum. It operates in the same adjacent microbiome consumer category and overlaps with Quorum's probiotic-derived technology positioning.

TypeBroad incumbent
Description

Seres is a clinical-stage microbiome therapeutics company that has commercialized an FDA-approved microbiome therapy. It is broader in scope and more pharma-oriented than Quorum, but operates in the same microbiome therapeutics category.

TypeEmerging player
Description

AOBiome develops live bacterial therapeutics for skin and systemic conditions, with Larry Weiss serving as former CMO. It is an emerging microbiome therapeutics peer with overlapping scientific advisor relationships and a related biological approach.

TypeDirect peer
Description

Pendulum develops microbiome-based interventions (notably Pendulum Glucose Control) and sells them DTC. It is a direct comparable to Quorum's model of translating microbiome science into consumer-facing products with clinical efficacy claims.

9Athletic Greens (AG1)
TypeDirect peer
Description

AG1 is a high-growth DTC daily nutrition supplement brand with strong digital marketing and subscription economics. It shares Quorum's DTC e-commerce, subscription-based revenue model and health-conscious consumer positioning.

TypeDirect peer
Description

Ritual is a science-forward DTC supplement brand selling daily essentials with subscription e-commerce. It shares Quorum's emphasis on clinical validation, transparent ingredient sourcing, and direct-to-consumer distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quorum Innovations

Microbiome Therapeutics / Dietary Supplementsquoruminnovations.com

Quorum Innovations is a Sarasota-based microbiome biotherapeutics company that sells Qi601™, an FDA GRAS-designated postbiotic supplement that binds microplastics in the gut, directly to health-conscious consumers via its qi601.com e-commerce storefront.

What Quorum Innovations does

Quorum Innovations is a privately held microbiome biotherapeutics company headquartered in Sarasota, Florida, founded in 2011 by physician-scientists Dr. Nicholas Monsul and Dr. Eva Berkes. The company develops barrier-based microbiome technologies originating from two DARPA-funded research programs on protective biotherapeutics for military warfighters. Its flagship technology, the Biofilm Shield™, is a non-living, biofilm-derived postbiotic aggregate produced from heat-inactivated Lactobacillus fermentum (Qi6 strain), which has received FDA Generally Recognized as Safe designation under GRN 000988. The aggregate forms self-organizing macrostructures approximately 200 micrometers in diameter with a cobblestone-like surface topology that selectively binds micro- and nanoplastics in the gastrointestinal tract, reducing microplastic adherence to human intestinal epithelial cells by up to 83% in laboratory studies.

The company's commercial product, Qi601™, launched in 2025 and is sold directly to consumers as a once-daily oral postbiotic supplement via the proprietary e-commerce storefront qi601.com. Supporting technology platforms include the MiNE™ (Microbiome isolates and Novel Extracts) discovery engine and the Probiomic® biotherapeutic framework, both of which underpin the current product and a potential pipeline of additional barrier-defense candidates. The company holds over 55 issued patents across more than 50 countries and has active research collaborations with Bayer Pharmaceuticals in women's health, as well as participation in the HHS STOMP federal initiative on microplastics.

Quorum operates with 1–10 employees, sells only in the United States through direct-to-consumer channels, and generates revenue from one-time purchases and subscription orders of Qi601 capsules. Its business model is product-led and science-marketing-driven, emphasizing peer-reviewed clinical evidence, FDA GRAS status, and a patented mechanism of action rather than traditional retail distribution or institutional sales.

Quorum Innovations firmographics

Firmographics
Name
Quorum Innovations
Legal name
Quorum Innovations
Website
https://quoruminnovations.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Quorum Innovations is a Sarasota-based microbiome biotherapeutics company that sells Qi601™, an FDA GRAS-designated postbiotic supplement that binds microplastics in the gut, directly to health-conscious consumers via its qi601.com e-commerce storefront.
Ownership category
akta.pro rank

Quorum Innovations industry classification

Industry
Product category
Microbiome Therapeutics / Dietary Supplements
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)

Keywords

  • Microbiome biotherapeutics
  • Postbiotic supplements
  • Microplastic detox
  • Biofilm shield technology
  • Human microbiome research

Where Quorum Innovations is headquartered

Location

Headquarters

HQ city
Sarasota
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Quorum Innovations business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Direct-to-Consumer Supplement Sales: Quorum generates revenue through direct sales of Qi601 capsules to consumers via its e-commerce platform at qi601.com. The product is sold as a daily oral supplement with pricing for individual bottles and potentially subscription options for recurring purchases.
  2. Consumer Direct Sales: One-time purchase of Qi601 supplement bottles through the company's e-commerce storefront, targeting health-conscious individual consumers concerned about microplastic exposure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Quorum Innovations product offering

Product offering

Core offering

Quorum Innovations develops and sells Qi601™, the world's first microplastic detox supplement. Qi601 is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum that forms a biofilm-like matrix in the gastrointestinal tract to bind and sequester micro- and nanoplastics, preventing their absorption into the body. The product is sold direct-to-consumer through the company's own e-commerce platform at qi601.com, supported by the proprietary MiNE™ discovery platform and Probiomic® biotherapeutic technology framework with 55+ issued patents worldwide.

Product overview

Quorum Innovations develops microbiome biotherapeutics centered on its flagship product Qi601™ Biofilm Shield™ — a patented, orally administered postbiotic supplement that forms a non-systemic gut biofilm matrix to bind and sequester micro- and nanoplastics. The technology portfolio includes the MiNE™ (Microbiome isolates and Novel Extracts) discovery platform and the Probiomic® technology framework. Qi601™ represents the first commercial application, with the platform technologies supporting its development and enabling future biotherapeutic pipeline candidates for barrier defense applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Qi601: The world's first microplastic detox product - a patented, orally administered postbiotic derived from Lactobacillus fermentum that forms a biofilm shield to bind micro- and nanoplastics in the gut.
  • MiNE™ Platform
  • ProBiomic™
  • Biofilm Shield™

Products and services

  • Qi601™ Qi601™ is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum (GRN 000988) that forms self-aggregating biofilm macrostructures (~200 µm) in the gastrointestinal tract to physically bind and sequester micro- and nanoplastics, helping prevent their absorption into the human body. Sold direct-to-consumer through qi601.com as a once-daily capsule supplement.

Quantifiable outcome

  • Up to 98% capture of nanoplastics in laboratory tests simulating digestive conditions
  • +3 more outcomes

Companies that use Quorum Innovations

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Quorum Innovations technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Quorum Innovations partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • HHS STOMP InitiativecoreStrategic or Co-development Partner · 15 April 2026Quorum Innovations was invited to participate in the HHS STOMP (Strategic Training for Opioid Microplastics) initiative in Washington D.C., recognizing the company as a subject matter expert on microplastics and human health. The company joins federal leadership and key stakeholders working to address microplastic exposure impacts, positioning Quorum at the forefront of national public health efforts.
  • Bayer PharmaceuticalscoreStrategic or Co-development PartnerBayer Pharmaceuticals partnered with Quorum in a joint development program exploring biofilm barrier protection technologies for women's health applications in intimate care products. This collaboration validated the translational potential of Quorum's barrier defense platform beyond military applications.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Quorum Innovations competitors and assessment

Company assessment

Direct peers

  • Seed Health: Seed is a science-led DTC microbiome company selling probiotic and synbiotic supplements with subscription e-commerce. Like Quorum, it markets clinically validated microbiome products directly to health-conscious consumers and emphasizes peer-reviewed research in its positioning.
  • Pendulum Therapeutics: Pendulum develops microbiome-based interventions (notably Pendulum Glucose Control) and sells them DTC. It is a direct comparable to Quorum's model of translating microbiome science into consumer-facing products with clinical efficacy claims.
  • Athletic Greens (AG1): AG1 is a high-growth DTC daily nutrition supplement brand with strong digital marketing and subscription economics. It shares Quorum's DTC e-commerce, subscription-based revenue model and health-conscious consumer positioning.
  • Ritual: Ritual is a science-forward DTC supplement brand selling daily essentials with subscription e-commerce. It shares Quorum's emphasis on clinical validation, transparent ingredient sourcing, and direct-to-consumer distribution.

Broad incumbents

  • Finch Therapeutics: Finch develops microbiome-based therapeutics with a focus on consortia-based drug products. It shares Quorum's microbiome therapeutics DNA but operates at a larger scale with a broader R&D pipeline and more established pharma partnerships.
  • Align (Procter & Gamble): Align is a leading digestive health probiotic brand owned by Procter & Gamble. It targets the same health-conscious consumer seeking gut health benefits but at mass-market scale across food, drug, and mass retail channels.
  • Culturelle (i-Health / Chr. Hansen): Culturelle is one of the largest clinically-backed probiotic supplement brands, owned by i-Health and now part of Chr. Hansen. It competes in the same digestive health probiotic category but with vastly broader retail distribution and brand recognition.
  • Seres Therapeutics: Seres is a clinical-stage microbiome therapeutics company that has commercialized an FDA-approved microbiome therapy. It is broader in scope and more pharma-oriented than Quorum, but operates in the same microbiome therapeutics category.

Emerging players

  • Symbiome: Symbiome is a microbiome-focused consumer brand founded by Larry Weiss, who serves as a Scientific Advisor to Quorum. It operates in the same adjacent microbiome consumer category and overlaps with Quorum's probiotic-derived technology positioning.
  • AOBiome: AOBiome develops live bacterial therapeutics for skin and systemic conditions, with Larry Weiss serving as former CMO. It is an emerging microbiome therapeutics peer with overlapping scientific advisor relationships and a related biological approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Quorum Innovations social profiles

Digital presence

Quorum Innovations compliance and trust

Trust signal

Compliance1 record

Quorum Innovations financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quorum Innovations leadership team

Management profile

Number of profiles

Profiles11 records

Quorum Innovations funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quorum Innovations M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quorum Innovations

What does Quorum Innovations do?

Quorum Innovations develops and sells Qi601™, the world's first microplastic detox supplement. Qi601 is a patented, orally administered, non-living postbiotic derived from heat-inactivated Lactobacillus fermentum that forms a biofilm-like matrix in the gastrointestinal tract to bind and sequester micro- and nanoplastics, preventing their absorption into the body. The product is sold direct-to-consumer through the company's own e-commerce platform at qi601.com, supported by the proprietary MiNE™ discovery platform and Probiomic® biotherapeutic technology framework with 55+ issued patents worldwide.

Is Quorum Innovations a public or private company?

Quorum Innovations is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Quorum Innovations founded?

Quorum Innovations was founded in 2011. It employs 1 to 10 people.

Where is Quorum Innovations based?

Quorum Innovations is headquartered in Sarasota, United States, in the North America region.

How does Quorum Innovations make money?

Two revenue lines are on record. Direct-to-Consumer Supplement Sales are the primary driver. The others are consumer Direct Sales.

Who are Quorum Innovations's main competitors?

Direct peers on record are Seed Health, Pendulum Therapeutics, Athletic Greens (AG1) and Ritual. Broad incumbents are Finch Therapeutics, Align (Procter & Gamble), Culturelle (i-Health / Chr. Hansen) and Seres Therapeutics. Emerging players are Symbiome and AOBiome.

Does Quorum Innovations have an API?

No public API is recorded for Quorum Innovations.

What industry is Quorum Innovations in?

Quorum Innovations's product category is Microbiome Therapeutics / Dietary Supplements. Its primary akta.pro industry code is HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics). Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SuperbCrewAn Interview With Eva A. Berkes, MD, Chief Scientific Officer And Co-Founder At Quorum InnovationsEva A. Berkes, MD, co-founder of Quorum Innovations, describes its Qi601 postbiotic that binds micro- and nanoplastics in the gut. The company reports a study showing Qi601 bound 92% of free nanoplastics in simulated digestion and plans a larger clinical study.EIN PresswireFIRST-IN-HUMAN STUDY DEMONSTRAES Qi601 CAN PHYSICALLY CAPTURE MICROPLASTICSA peer-reviewed study published in Frontiers in Microbiology reports the first human proof-of-concept that Qi601, a heat-inactivated postbiotic, physically captures microplastics. In a human mouth study, Qi601 bound approximately 91% of microplastics from chewing gum, and simulated digestion showed 92% depletion of free nanoplastics. Larger controlled human studies are underway to demonstrate clinical efficacy.New ScientistSupplement that binds to microplastics may remove them from our bodyQuorum Innovations, a biopharmaceutical company in Florida, has announced results from what it claims is the first human trial of a microplastic-removal supplement called Qi601, made from dead bacteria cell walls. The postbiotic demonstrated that up to 92% of nanoplastics bound to it in lab tests simulating the digestive system, and in a small human trial, it reduced freely floating plastic particles in saliva from 2,152 to 185 after participants chewed gum. Researchers caution the study hasn't proven the particles were prevented from entering gut cells or excreted, and outside experts note the supplement would not address inhaled microplastics or the continuous nature of exposure.EIN PresswireFirst Human Study Shows Qi601 Probiotic Binds Microplastics and Retains 98% During DigestionA newly released study reports the first published demonstration that a technology designed to physically bind microplastics in humans is feasible. The study found Qi601 maintained binding through digestion, retaining 98% of its microplastic-binding capacity.EIN PresswireQuorum Innovations Among First Selected to Help Shape Federal STOMP Initiative as HHS Highlights Microplastics as ToxicQuorum Innovations was among the first organizations invited to participate in the federal STOMP initiative, a $144 million effort to address microplastic exposure. The company's involvement aligns with HHS's renewed focus on microplastics as toxic, and it has developed QI601, a product that binds microplastic particles.PR NewswireQuorum Innovations to Present New Research Showing Breakthrough Method for Capturing NanoplasticsQuorum Innovations announced that its proprietary Qi601™ technology can rapidly bind nanoplastics, demonstrated in peer-reviewed research accepted at the TechConnect World Innovation Conference. The research showed up to 98% capture of nanoplastics in laboratory tests, which could reduce human exposure to these particles. The company is expanding its biological barrier technology to address microplastics and nanoplastics in everyday environments.MorningstarQuorum Innovations to Present New Research Showing Breakthrough Method for Capturing NanoplasticsQuorum Innovations announced that peer-reviewed research demonstrating its proprietary Qi601™ technology can rapidly capture nanoplastics has been accepted for presentation at the 29th Annual TechConnect World Innovation Conference in Raleigh, North Carolina, on March 10, 2026. The study, conducted by company researchers, found that in laboratory tests simulating digestive conditions, Qi601 captured up to 98% of nanoplastics, suggesting it may reduce absorption of these particles into the body. Qi601 is a non-living postbiotic derived from Lactobacillus fermentum, a probiotic strain recognized as safe by the FDA, and represents work building on the company's prior DARPA-supported research on biological barrier technologies.PR NewswireA Microscopic Discovery With Massive Implications: Two Physicians Uncover a New Biological Defense Against MicroplasticsQuorum Innovations, a biotechnology company founded by physician-scientists Nicholas T. Monsul and Eva Ann Berkes, announced a breakthrough microbiome discovery—a naturally inspired protective biofilm capable of intercepting microplastics before they enter human tissue, demonstrating up to 98% effectiveness in binding and expelling microplastics from the digestive system in laboratory testing. The science was originally developed through two research awards from DARPA for military applications protecting warfighters from chemical and biological threats, and is now being explored as a civilian application for plastic exposure. The discovery coincides with rising legislative attention to plastics and human health, including the proposed Microplastics Safety Act (H.R. 4486) and MAHA public-health initiatives.